GxP Compliance

Part 11 Validation: Using Make.com in GxP Lab Workflows

Mid-market life sciences labs can use Make.com to accelerate workflows, but they must meet 21 CFR Part 11 and EU Annex 11 controls to avoid compliance exposure. This guide outlines a pragmatic, validation-first approach—covering RBAC, environment segregation, audit trails, checksums, e-signatures, and an actionable 30/60/90-day plan—to deliver speed without risking data integrity. It also details ROI metrics and common pitfalls so teams can scale automation confidently.

• 12 min read

Part 11 Validation: Using Make.com in GxP Lab Workflows

1. Problem / Context

Mid-market life sciences, pharma, and medical device labs are under pressure to accelerate sample throughput, reduce manual data entry, and maintain impeccable data integrity. Low-code orchestration tools like Make.com can connect LIMS, ELN, QMS, and instrument data with minimal engineering lift—exactly what lean teams need. But without 21 CFR Part 11 and EU Annex 11 controls, these automations can create compliance exposure: unvalidated flows altering regulated records, weak e-signature patterns, audit trails that miss user/timestamp/reason-for-change, and time synchronization gaps that erode trust in records.

The challenge is twofold: deliver operational gains quickly while meeting GxP validation expectations. Mid-market organizations rarely have large CSV/QA teams or dedicated platform engineers. The result? Shadow workflows, insufficient change control, and missing validation documentation. A pragmatic, governance-first approach lets you keep Make.com’s agility while satisfying Part 11 requirements.

2. Key Definitions & Concepts

  • 21 CFR Part 11 (and EU Annex 11): Regulations governing electronic records and electronic signatures in GxP contexts. Require identity controls, audit trails, integrity, traceability, and validation.
  • GxP: Good practice regulations (GLP, GCP, GMP) covering lab, clinical, and manufacturing contexts where data integrity and product quality are critical.
  • Make.com: A low-code workflow and integration platform (iPaaS) used to orchestrate tasks, move data, and trigger actions across systems.
  • IQ/OQ/PQ: Installation, Operational, and Performance Qualification—the backbone of a validation package for critical workflows.
  • RBAC: Role-based access control to restrict who can design, deploy, approve, and run workflows.
  • Environment segregation: Separation of development, test/validation, and production to prevent unvalidated changes reaching production.
  • Audit trail: An immutable, reviewable log capturing who did what, when, and why.
  • Checksum/Hashing: Cryptographic fingerprints (e.g., SHA-256) to verify file integrity from instrument to archive to LIMS.
  • HITL: Human-in-the-loop checkpoints where QA/QA Ops must review and approve before promotion or release.
  • Policy-as-code: Machine-enforced governance rules that block deployments that violate pre-set controls.

3. Why This Matters for Mid-Market Regulated Firms

For $50M–$300M organizations, validation overhead can stall automation initiatives. Yet, manual transcriptions, duplicate entry, and email-driven approvals create delays and deviation risk. Make.com offers speed and affordability, but it must be wrapped in Part 11-grade controls. Done right, you’ll cut cycle times and human error while reducing audit findings. Done wrong, you risk findings for improper e-signatures, missing reason-for-change, or unverifiable timestamps. A balanced approach preserves agility while protecting your license to operate.

Kriv AI, a governed AI and agentic automation partner for mid-market firms, helps teams thread this needle by embedding validation, auditability, and change control into the orchestration layer—so lean organizations can automate confidently without compromising compliance.

4. Practical Implementation Steps / Roadmap

  1. Classify workflows by GxP criticality

    • Inventory current and proposed Make.com scenarios.
    • Tag data elements and records that are Part 11-relevant (e.g., LIMS sample results, batch disposition, deviation records).
    • Separate GxP-critical vs. non-GxP flows; apply validation proportional to risk.
  2. Architect for control

    • Establish dev/test/prod workspaces; disable direct edits in prod.
    • Define RBAC: maker, reviewer, approver, operator; restrict API keys and webhooks.
    • Enforce time synchronization (NTP) across Make.com, LIMS/ELN, file stores, and identity providers.
    • Use SSO with MFA and group-based provisioning.
  3. Design integrity and signature patterns

    • Implement checksum/hashing for instrument files and attachments; store hash alongside metadata.
    • Route Part 11-significant steps through controlled e-signature nodes requiring dual approval for release/disposition.
    • Ensure audit trails log user, timestamp (UTC), and reason for change; centralize logs to a SIEM/immutable store.
  4. Build the validation package

    • Create URS/FRS and risk assessment per scenario.
    • Author IQ/OQ/PQ protocols and a traceability matrix; predefine expected results and objective evidence capture.
    • Plan negative tests (e.g., failed hash verification, time drift, permission errors).
  5. Implement with guardrails

    • Adopt naming/versioning conventions for scenarios; externalize secrets; parameterize endpoints.
    • Add policy-as-code gates that block promotion if tests fail or documentation is incomplete.
    • Configure notifications to QA for HITL approvals before moving to production.
  6. Operate and maintain

    • Establish SOPs/work instructions and training records; define periodic review cadence.
    • Instrument monitoring and alerts; capture incident tickets and CAPAs.
    • Use documented change control for updates; re-validate impacted steps.

5. Governance, Compliance & Risk Controls Needed

  • Formal validation (IQ/OQ/PQ) for GxP-critical scenarios, with complete traceability to URS/FRS.
  • RBAC and least privilege, including separation of duties between builders and approvers.
  • Environment segregation (dev/test/prod) with documented promotion steps and QA sign-off.
  • Time synchronization across all components to prevent timestamp discrepancies.
  • Checksum/hashing for files and attachments; verify integrity at each hop.
  • Immutable audit trails capturing user, timestamp, and reason; centralized log retention aligned with SOP.
  • e-Record/e-signature controls with dual approval where required by procedure.
  • Documented change control and version history; revalidation triggers for material changes.
  • Policy-as-code enforcement to prevent configuration drift and unauthorized changes.
  • Data lineage for prompts, parameters, and source systems so reviewers can reconstruct each run.

Kriv AI often complements this stack by auto-generating validation test suites and evidence packs, enforcing policy-as-code gates, and maintaining end-to-end lineage—strengthening Part 11 and Annex 11 readiness without heavy overhead on lean teams.

6. ROI & Metrics

Executives should expect measurable operational and compliance outcomes:

  • Cycle time reduction: Example—transferring instrument result files to LIMS with automated integrity checks and dual e-signature for release can reduce handling from ~12 minutes per sample to ~5 minutes, accelerating batch review without sacrificing control.
  • Error rate decline: Eliminating manual transcriptions and enforcing hash checks can reduce data entry deviations and missing attachment incidents.
  • Right-first-time: Percentage of workflows promoted to production without rework after QA review.
  • Audit readiness: Time to compile objective evidence for an inspection (from days to hours) due to pre-packaged evidence and immutable logs.
  • Labor savings: Reallocating FTE hours from routine routing/verification to higher-value QA oversight.
  • Payback period: With 10–20 high-volume lab workflows automated under validation, many mid-market labs see payback in 6–12 months, depending on volume and baseline deviation rates.

7. Common Pitfalls & How to Avoid Them

  • Unvalidated changes in production: Lock prod; require QA approvals and policy-as-code gates before promotion.
  • Weak e-signature patterns: Implement identity-bound signatures with dual approval for critical steps and capture reason-for-change.
  • Missing or mutable audit trails: Use immutable logging with user, timestamp, and action; forward to centralized retention.
  • Time drift: Enforce NTP across Make.com and connected systems; alert on clock skew.
  • No file integrity verification: Hash files at ingest and re-verify at each hop; block workflows on mismatch.
  • Incomplete documentation: Maintain URS/FRS, risk assessments, IQ/OQ/PQ, SOPs, training records, and change logs.
  • Over-privileged builders: Enforce RBAC and separation of duties; avoid shared admin tokens and rotating credentials without record.

30/60/90-Day Start Plan

First 30 Days

  • Inventory all existing and proposed Make.com workflows; classify GxP criticality.
  • Map systems (LIMS, ELN, QMS, DMS, instruments) and data elements requiring Part 11 controls.
  • Establish governance boundaries: RBAC roles, environment segregation, time sync policy, logging destinations.
  • Draft URS/FRS and initial risk assessments for top 3–5 critical scenarios.

Days 31–60

  • Build validation-ready architectures for priority workflows with hashing, audit trail, and e-signature checkpoints.
  • Author and execute IQ/OQ protocols; capture evidence; remediate gaps.
  • Implement HITL gates: QA/QA Ops sign-off before promotion; dual approval where required.
  • Stand up policy-as-code enforcement and change control; pilot in test environment.

Days 61–90

  • Execute PQ in production under controlled monitoring; finalize validation package.
  • Train users; record read-and-understand acknowledgments; publish SOPs and work instructions.
  • Baseline KPIs (cycle time, error rates, right-first-time, evidence prep time); plan quarterly reviews.
  • Scale to additional workflows using the same patterns; institutionalize revalidation triggers and periodic review.

9. Industry-Specific Considerations

  • Pharma and biotech labs: Pay close attention to chain-of-custody, stability studies, and batch disposition flows; align with data integrity principles (ALCOA+).
  • Medical device labs: Tie Make.com flows to design history file (DHF) and device master record (DMR) evidence needs; ensure Annex 11 expectations for periodic evaluation.
  • CRO/clinical labs: If applicable, coordinate with sponsor requirements and ensure that e-signature identities align with contractual obligations and audit readiness.

10. Conclusion / Next Steps

Make.com can be safely used in GxP lab workflows when wrapped in validation, integrity, and governance controls aligned to 21 CFR Part 11 and EU Annex 11. The winning formula is simple: build once with the right controls (IQ/OQ/PQ, RBAC, segregation, time sync, checksums, immutable audit trails), then scale confidently.

If you’re exploring governed Agentic AI for your mid-market organization, Kriv AI can serve as your operational and governance backbone. As a mid-market-focused partner, Kriv AI helps with data readiness, MLOps, and governance—and can auto-generate validation test suites, evidence packs, and policy-as-code gates so your teams move faster without increasing risk.